|

Lung Cancer Clinical Trials in Utah

79 recruiting studies across 9 cities

All Trials in Utah

Phase
Trial Phase Location
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3American Fork
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2Draper
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 2Ogden
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3Ogden
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPhase 3Ogden
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationPhase 1Salt Lake City
A Phase 1 Study of LNCB74 in Advanced Solid TumorsPhase 1Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsPhase 1/2Salt Lake City
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPhase 2Salt Lake City
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1Salt Lake City
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2Salt Lake City
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerPhase 2Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsPhase 1Salt Lake City
A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsPhase 1Salt Lake City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPhase 1Salt Lake City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Phase 3Salt Lake City
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionPhase 2/3Salt Lake City
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3Salt Lake City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Salt Lake City
BBO-11818 in Adult Subjects With KRAS Mutant CancerPhase 1Salt Lake City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerN/ASalt Lake City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Salt Lake City
Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net ClinicsN/ASalt Lake City
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsPhase 1/2Salt Lake City
Improving Care for Rural Patients With Solid TumorsN/ASalt Lake City
JAB-2485 Activity in Adult Patients With Advanced Solid TumorsPhase 1/2Salt Lake City
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Salt Lake City
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data—Salt Lake City
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—Salt Lake City
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerPhase 1Salt Lake City
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) StudyN/ASalt Lake City
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Salt Lake City
SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier—Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Salt Lake City
Safety and Durability of Sirolimus for Treatment of LAM—Salt Lake City
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossPhase 1/2Salt Lake City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Phase 2/3Salt Lake City
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerPhase 1/2Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3Salt Lake City
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Phase 3Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/2Salt Lake City
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2Salt Lake City
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPhase 1/2Salt Lake City
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Salt Lake City
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsPhase 2Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Salt Lake City
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPhase 1/2Salt Lake City
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsPhase 1/2West Valley City
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsPhase 1West Valley City
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1West Valley City
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1West Valley City
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLCPhase 1/2West Valley City
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/2West Valley City
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsPhase 1/2West Valley City
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2West Valley City
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesPhase 1West Valley City
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsPhase 1West Valley City
A Study of LY4175408 in Participants With Advanced CancerPhase 1West Valley City
A Study of MGC026 in Participants With Advanced Solid TumorsPhase 1West Valley City
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1West Valley City
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsPhase 1West Valley City
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsPhase 1West Valley City
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1West Valley City
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesPhase 1/2West Valley City
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPhase 1West Valley City
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)Phase 1/2West Valley City
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsPhase 1West Valley City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCPhase 1/2West Valley City
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsPhase 1West Valley City
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPhase 1West Valley City
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2West Valley City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2West Valley City
Study of CP-383 in Patients With Advanced or Metastatic Solid TumorsPhase 1/2West Valley City
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 1West Valley City
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPhase 1/2West Valley City

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.